PureSense™ — precision brain health diagnostic

Predicting Familial Alzheimer’s Disease up to 20 years before clinical symptoms

ViewMind has demonstrated in a double-blind clinical study that it can detect minor abnormalities in eye movements that correlate with the early accumulation of proteins in specific parts of the brain that predict Familial Alzheimer's disease — decades before clinical symptoms.

Scientific partnerships:
ViewMind difference

ViewMind uniquely provides a precision diagnosis of neurocognitive resources and changes in the brain

An individual with a high cognitive reserve may have accumulations of proteins in the brain and yet live out a normal healthy life with no cognitive impairments. For a complete understanding of brain health, it is critical to assess neurocognitive resources, changes in the brain, as well as pathological or biochemical changes. ViewMind’s diagnostic solutions have been clinically validated on over 2,000 subjects.

Before Viewmind

Pen-and-paper neurocognitive test batteries that lack objectivity
Invasive, costly, late-stage imaging or lumbar puncture diagnostic tests
Costly and complex imaging such as an fMRI or EEG

With Viewmind

A precise, standardized, quantifiable assessment of clinical symptoms and neurocognitive resources
Non-invasive, early-stage assessment that analyzes eye movement pattern abnormalities, with results that closely correlate with pathological tests (CSF, Amyloid-PET)
Assessment at the level of brain region with high correlation to fMRI and EEG
Analysis

Studies

A novel peripheral biomarker for Mild Cognitive Impairment and Alzheimer’s disease
Mario A Parra, Marcela Schumacher, and Gerardo Fernandez
“[E]ye-tracking measures combined with cognitive markers for AD(STMB) can (1) enrich the clinical phenotype of this type of dementia,(2) unveil novel features of AD dementia unknown to date.”
Eye Movement Alterations During Reading in Patients With Early Alzheimer Disease
Gerardo Fernandez, Pablo Mandolesi, Nora P. Rotstein, Oscar Colombo, Osvaldo Agamennoni, and Luis E. Politi
“The present study shows that patients with mild AD evidenced marked alterations in eye movement behavior during reading, even at early stages of the disease.”
Eye Movement Behavior Analyses for Studying Cognitive Performance and Conversion to Pathologies
Gerardo Fernández, Paola Buedo, David Orozco and Osvaldo Agamennoni
“Our results show that it is possible to develop anew, objective, noninvasive, and economical technique to evaluate mild cognitive impairments that could help in the early and proper diagnosis of [neuropsychiatric] pathologies.”
A novel Digital Cognitive Biomarker for Mild Cognitive Impairment and Alzheimer’s disease
Gerardo Fernández, Marcela Schumacher, David Orozco, Gustavo Sgrilli, Gustavo Echevarria, Ramiro Linares and Mario A Parra
"Taken together, the results above suggest that ViewMindcan (1)unveil novel features of the ACS unknown to date,and (2) provide amore sensitive tool which can detect and trace aspectsof such aphenotype in people at risk, thus helping to ascertainthe presence ofthe prodromal stages of AD."

How ViewMind gathers and analyzes eye movement patterns to produce accurate, AI-powered results

Medical-grade VR headset
VR headset enables ViewMind to conduct an analysis of eye movement, the purest source of data for sensitive and specific results
Eye movement assessment
Eye movements follow a reproducible pattern in in healthy individuals and in individuals with neurodegenerative disorders.
AI-based analysis
ViewMind’s patented digital biomarker software can identify minor deviations in oculomotor patterns, quantify them and correlate them to specific pathologies, neurocognitive functions and related areas of the brain.

Change the future of neurocognitive disease prevention and management

© Copyright Viewmind 2018 - 2023 | All rights reserved